[1]Brain R, Russell SN, Matthew TN, et al.Fibrocystic diseasesof the liver[M].∥Thomas DB, Teresa LW, Michael PM.Zakim and Boyer’s Hepatology.Philadelphia, USA:Saun-ders, 2006:1329-1353.
|
[2]Turkbey B, Ocak I, Daryanani K, et al.Autosomal recessivepolycystic kidney disease and congenital hepatic fibrosis (ARPKD/CHF) [J].Pediatr Radiol, 2009, 39 (2) :100-111.
|
[3]Yasoshima M, Sato Y, Furubo S, et al.Matrix proteins ofbasement membrane of intrahepatic bile ducts are degradedin congenital hepatic fibrosis and Caroli's disease[J].JPathol, 2009, 217 (3) :442-451.
|
[4]Bergmann C, Senderek J, Windelen E, et al.Clinical conse-quences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD) [J].KidneyInt, 2005, 67 (3) :829-848.
|
[5]Drenth JP, Chrispijn M, Bergmann C, et al.Congenital fibro-cystic liver diseases[J].Best Pract Res Clin Gastroenterol, 2010, 24 (5) :573-584.
|
[6]Shorbagi A, Bayraktar Y.Experience of a single center withcongenital hepatic fibrosis:a review of the literature[J].World J Gastroenterol, 2010, 16 (6) :683-690.
|
[7]Rockey DC.Current and future anti-fibrotic therapies for chro-nic liver disease[J].Clin Liver Dis, 2008, 12 (4) :939-962.
|